These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 33637415)

  • 21. [Finerenone cardiorenal effects and its placement in treatment of chronic kidney disease in patients with type 2 diabetes mellitus: A review].
    Salukhov VV; Shamkhalova MS; Duganova AV
    Ter Arkh; 2023 Apr; 95(3):261-273. PubMed ID: 37167149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems.
    Kolkhof P; Lawatscheck R; Filippatos G; Bakris GL
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease.
    Lima Posada I; Soulié M; Stephan Y; Palacios Ramirez R; Bonnard B; Nicol L; Pitt B; Kolkhof P; Mulder P; Jaisser F
    J Am Heart Assoc; 2024 Jun; 13(12):e032971. PubMed ID: 38842271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
    Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
    JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
    Pandey AK; Bhatt DL; Cosentino F; Marx N; Rotstein O; Pitt B; Pandey A; Butler J; Verma S
    Eur Heart J; 2022 Aug; 43(31):2931-2945. PubMed ID: 35713973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Finerenone: First Approval.
    Frampton JE
    Drugs; 2021 Oct; 81(15):1787-1794. PubMed ID: 34519996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of the Non-Steroidal Mineralocorticoid Antagonist Finerenone in Cardiorenal Management.
    Beavers CJ
    Curr Cardiol Rep; 2022 Dec; 24(12):1785-1790. PubMed ID: 36272052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.
    Katayama S; Yamada D; Nakayama M; Yamada T; Myoishi M; Kato M; Nowack C; Kolkhof P; Yamasaki Y;
    J Diabetes Complications; 2017 Apr; 31(4):758-765. PubMed ID: 28025025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renoprotective Effects of Mineralocorticoid Receptor Antagonists Against Diabetic Kidney Disease.
    Bayne S; LeFevre J; Olstinske K; Ravindran S; Munusamy S
    Adv Biol (Weinh); 2024 Mar; 8(3):e2300496. PubMed ID: 38065929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic perspective: evolving evidence of nonsteroidal mineralocorticoid receptor antagonists in diabetic kidney disease.
    Yao L; Liang X; Wang P
    Am J Physiol Endocrinol Metab; 2023 Jun; 324(6):E531-E541. PubMed ID: 37166263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time-Varying Cardiovascular Effects of Finerenone in Diabetic Kidney Disease: Insights From FIDELIO-DKD and FIGARO-DKD Trials.
    Al-Kindi S; Motairek I; Janus S; Deo S; Rahman M; Neeland IJ; Rajagopalan S
    J Am Coll Cardiol; 2022 Nov; 80(19):1855-1856. PubMed ID: 36328698
    [No Abstract]   [Full Text] [Related]  

  • 32. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
    Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
    Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone.
    Rico-Mesa JS; White A; Ahmadian-Tehrani A; Anderson AS
    Curr Cardiol Rep; 2020 Sep; 22(11):140. PubMed ID: 32910349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overview of the safety, efficiency, and potential mechanisms of finerenone for diabetic kidney diseases.
    Chen W; Zheng L; Wang J; Lin Y; Zhou T
    Front Endocrinol (Lausanne); 2023; 14():1320603. PubMed ID: 38174337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.
    Barrera-Chimal J; Lima-Posada I; Bakris GL; Jaisser F
    Nat Rev Nephrol; 2022 Jan; 18(1):56-70. PubMed ID: 34675379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease.
    Raj R
    Curr Opin Nephrol Hypertens; 2022 May; 31(3):265-271. PubMed ID: 35165249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease.
    Ortiz A; Ferro CJ; Balafa O; Burnier M; Ekart R; Halimi JM; Kreutz R; Mark PB; Persu A; Rossignol P; Ruilope LM; Schmieder RE; Valdivielso JM; Del Vecchio L; Zoccali C; Mallamaci F; Sarafidis P;
    Nephrol Dial Transplant; 2023 Jan; 38(1):10-25. PubMed ID: 33944938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes.
    Ruilope LM; Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Sarafidis P; Schmieder RE; Joseph A; Rethemeier N; Nowack C; Bakris GL;
    Hypertension; 2022 Dec; 79(12):2685-2695. PubMed ID: 36252131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes.
    Lerma EV; Wilson DJ
    Expert Rev Clin Pharmacol; 2022 May; 15(5):501-513. PubMed ID: 35762406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular and Renal Benefit of Novel Non-steroidal Mineralocorticoid Antagonists in Patients with Diabetes.
    Kintscher U
    Curr Cardiol Rep; 2023 Dec; 25(12):1859-1864. PubMed ID: 37991625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.